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Background
Neoadjuvant chemotherapy is administered to control
disease, make surgical resection possible and increase
the possibility of breast tissue conservation. A further
advantage of neoadjuvant therapy is that it helps to
assess chemo-sensitivity to a particular agent. Induction
of a pathological complete response (pCR) is one of the
primary goals of neoadjuvant therapy in order to achieve
a better disease-free and overall survival. Experimental
data suggest that BRCA1 related breast cancer may have
increased sensitivity to platinum-based chemotherapy,
but clinical data are limited. The aim of this study was
to evaluate the frequency of complete pathologic
response after neo-adjuvant treatment with cisplatin
chemotherapy in women with breast cancer and a
BRCA1 mutation.
Methods
Twenty five women with breast cancer and a BRCA1
mutation with stage I, II, and III breast cancer between
December 2006 and July 2009 were entered into this
study. Patients were treated with cisplatin 75 mg/m
2
intravenously every three weeks for four cycles. After
chemotherapy, patients underwent surgery and were
assessed for pathologic response in both the breast and
axillary lymph nodes. Complete pathologic response was
defined as no residual invasive disease in both the breast
and axilla, however ductal carcinoma in situ was allowed.
Results
Thirty eight patients were enrolled in the study. Twenty
three patients had tumors of greater than two centi-
meters (60%) and eleven patients had positive lymph
nodes at diagnosis (29%). Thirty five patients completed
four cycles of cisplatin (92%) and three patients com-
pleted two cycles (8%). Clinical complete response was
observed in twenty eight patients (74%). Pathologic
complete response was observed in twenty three
(60,5%).
Conclusions
Platinum-based chemotherapy is effective in a high pro-
portion of patients with BRCA1-associated breast can-
cers. Clinical trials are warranted to determine the
optimum treatment for this subgroup of breast cancer
patients.
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